Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy-Reference-Cited by-同舟云学术

Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy

Published:2011-03-29 Issue:4 Volume:28 Page:251-269
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Therapy

Author:

Vachiéry Jean-Luc

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-011-0005-5.pdf

Reference66 articles.

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–2537.

2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–S54.

3. Jansa P, Ambroz D, Maresova J, Polacek P, Aschermann M, Linhart A. Pulmonary arterial hypertension-contemporary management strategy. Bratisl Lek Listy. 2009;110:603–608.

4. Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs. 2010;19:469–488.

5. Umar S, Steendijk P, Ypey DL, et al. Novel approaches to treat experimental pulmonary arterial hypertension: a review. J Biomed Biotechnol. 2010;2010:702–836.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelium‐dependent contraction: The non‐classical action of endothelial prostacyclin, its underlying mechanisms, and implications;The FASEB Journal;2021-08-27

2. Differential properties of E prostanoid receptor‐3 and thromboxane prostanoid receptor in activation by prostacyclin to evoke vasoconstrictor response in the mouse renal vasculature;The FASEB Journal;2020-10-13

3. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery;Journal of Controlled Release;2020-10

4. Beraprost Upregulates K_V Channel Expression and Function via EP₄ Receptor in Pulmonary Artery Smooth Muscle Cells Obtained from Rats with Hypoxia-Induced Pulmonary Hypertension;Journal of Vascular Research;2019

5. Prostanoid EP2 Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells;International Journal of Molecular Sciences;2018-08-12